TrialDrug metabolism and disposition: the biological fate of chemicals2011

Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Sarah J Schrieber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.